MARVIN I. SIEGEL, PH.D SENIOR PHARMACEUTICAL/BIOTECH EXECUTIVE PROFESSIONAL PROFILE
Senior Executive leader with expertise building companies and managing strategic alliances. Member of board of directors of two biotech companies. Managed a joint venture between two biotechnology companies and a $200 million joint development program between a biotech and a major pharmaceutical company. Negotiated and managed a $20M European process development and manufacturing contract and one in the US. Executed development program for successful out-license of a product candidate. Demonstrated expertise in strategic planning, competitive intelligence, business development and leadership of business leaders, scientists and physicians. Successfully managed multi-disciplinary teams and executed large projects in the US and Globally. Managed R & D for Claritin, Nasonex, Asmanex and Elocon. Author of 170 publications and holder of 22 patents. Ph.D. Physiological Chemistry, The Johns Hopkins School of Medicine; M.A. Chemistry, Columbia University; B.S. Chemistry, Lafayette College; Advanced Management Program, Fuqua School of Business, Duke University.
> Organizational Development > Joint Venture/Corporate Alliance Intellectual Property > R & D SELECTED ACHIEVEMENTS
Led the research that resulted in the marketing of Claritin, the world’s leading non-
sedating antihistamine, producing annual sales of more than $4 billion. Led the R & D resulting in the marketing of Nasonex, Asmanex and Elocon, each with annual sales of hundreds of millions of dollars.
Led the entire program of research, process development, manufacturing, clinical and
regulatory affairs for a biotech company’s first IND through Phase III trials.
Directed semi-annual reviews of business strategy objectives to determine changes
necessary to meet overall objectives. Sometimes required revising short term plans.
Opened and led the US Division of Canadian Biotechnology Company, recruiting and
hiring experienced professional staff and leading “virtual office” for process development, manufacturing, clinical and regulatory affairs as well as project management. Managed $30M peak annual Research and Development Budget.
Realizing a need for additional capital when taking over day to day operational
decisions, approached potential investors, identified and secured $15M in mezzanine financing for private US company.
Searched and secured a US intermediary to identify and mold a new approach to
finding US investors for a Canadian public company in need of capital. Identified a colleague in NY and collaboratively secured US investment that gave the needed comfort to Canadian investors raising $19 million.
REBBESON, INC BLUE BELL, PA 1997-Present
Consulting company to Biotech and Pharmaceutical companies
Consultant to entrepreneurs and entrepreneurial companies with projects in Drug
Development, Strategic Planning and Organizational Development
Clients include companies in Biotech, Pharmaceuticals and Consumer Products.
Chairman, Board of Directors, Acting Chief Executive Officer
Guided strategic planning and corporate development
STRESSGEN BIOTECHNOLOGIES VICTORIA, BC CANADA & COLLEGEVILLE, PA 1997-2006
Development of novel therapeutic vaccines.
Executive Vice President Vice President
Led Research, Development, Medical and Regulatory Affairs taking biomolecule from
Headed operating committee for a $20M joint venture.
Negotiated contract and managed $20M international process development and
Represented company to investment analysts, venture capitalists and individual
DELTA PHARMACEUTICALS INC. (NOW ARDENT) DURHAM, NC 1997-1999
Discovery and development of novel drugs for management of acute and chronic pain.
Member, Board of Directors
Guided strategic planning, organizational and business development and provided lead
TERRAPIN TECHNOLOGIES (NOW TELIK) PALO ALTO, CA 1995-1997
Drug discovery in oncology, diabetes and allergy.
Identified, negotiated and secured $15M of mezzanine financing
Responsible for R & D programs for the company
SCHERING PLOUGH (NOW MERCK) KENILWORTH, NJ 1982-1994
Global Pharmaceutical Company with revenues exceeding $6B
Vice President (Presidential Fellow) Senior Director
Led R & D for Claritin, Asmanex, Nasonex and Elocon
Education Ph.D Physiological Chemistry The Johns Hopkins University School of Medicine M.A. Chemistry Columbia University B.S. Chemistry Lafayette College Advanced Management Program Fuqua School of Business, Duke University
Underhook/In-Line Strain Gauge Lift Link with Remote Telemetry Linked Display LIFT LINK SYSTEM Ranges 1 tonne to 500 tonne CHARACTERISTICS ET LIFT LINK Ranges (F.R.): 1, 2, 5, 12, 25, 35, 50, 100, 250, 500 tonne Designed for use with standard Accuracy: Lifting Shackles Temperature Range: Safe Overload: Link Sealed to IP67 Ultimate Overload: Display Seal
Prepared by: Alan Ball ON Semiconductor http://onsemi.com APPLICATION NOTE Introduction the high side or an n-channel FET can be added in the lowSemiconductor’s eFuses offer low cost, lowimpedance solutions for bus protection and offer muchN-channel FETs are more cost effective and are normallyfaster protection than many fuse solutions. They are anpreferred if it is acceptab